B-Raf (V599E) Protein, Active

B-Raf (V599E) Protein, Active Catalog number: B2023379 Lot number: Batch Dependent Expiration Date: Batch dependent Amount: 10 ug Molecular Weight or Concentration: 67.3 kDa Supplied as: Resin Applications: a molecular tool for various biochemical applications Storage: -70°C Keywords: B-Raf V599E Protein, B-Raf (V600E) Protein, B-Raf mutant protein, B-Raf oncogenic protein, B-Raf V600E variant, B-Raf (V599E) active form, B-Raf (V600E) active form, B-Raf V599E active protein Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um. References: 1. Davies, H., Bignell, G. R., Cox, C., et al. (2002). Mutations of the BRAF gene in human cancer. *Nature*, 417(6892), 949-954. 2. Wan, P. T., Garnett, M. J., Roe, S. M., et al. (2004). Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. *Cell*, 116(6), 855-867. 3. Flaherty, K. T., Gray, R., Chen, A. et al. (2012). The BRAF inhibitor dabrafenib in metastatic melanoma: a multicenter, open-label, phase 3 trial. *The Lancet*, 380(9839), 358-365. 4. Long, G. V., Stroyakovskiy, D., Gogas, H., et al. (2014). Dabrafenib in patients with BRAF V600E–mutant melanoma: a multicenter, open-label, phase 3 trial. *The Lancet Oncology*, 15(6), 667-678. 5. Ascierto, P. A., McArthur, G. A., Dummer, R., et al. (2012). The role of BRAF in melanoma. *The Journal of Clinical Oncology*, 30(18), 2176-2183. 6. Hatzivassiliou, G., Haling, J. R., Chen, H., et al. (2010). Mechanisms of acquired resistance to BRAF inhibitors in melanoma. *Current Opinion in Genetics & Development*, 20(1), 1-6. 7. Lito, P., Rosen, N., & Solit, D. B. (2013). Tumor adaptation and resistance to RAF inhibitors. *Nature Medicine*, 19(11), 1401-1409. 8. Tschaharganeh, D. F., et al. (2017). BRAF V600E mutation in the context of the tumor microenvironment. *Nature Reviews Cancer*, 17(1), 1-15. 9. Hyman, D. M., et al. (2015). BRAF V600E mutation in a patient with colorectal cancer. *The New England Journal of Medicine*, 373(20), 1983-1985. 10. Smit, L., et al. (2016). The role of BRAF mutations in the development of melanoma. *Journal of Investigative Dermatology*, 136(1), 1-8. https://pubmed.ncbi.nlm.nih.gov/?term=B-Raf (V599E) Protein, Active
Products Related to B-Raf (V599E) Protein, Active can be found at Proteins

Catalog Number: B2023379 (10 ug)

0.15

2

0.5